Last --
Change Today 0.00 / 0.00%
Volume 0.0
AEMAY On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd-sponsored adr (AEMAY) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
32.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALCHEMIA LTD-SPONSORED ADR (AEMAY)

Related News

No related news articles were found.

alchemia ltd-sponsored adr (AEMAY) Related Businessweek News

No Related Businessweek News Found

alchemia ltd-sponsored adr (AEMAY) Details

Alchemia Limited, a biotechnology company, is engaged in the discovery and development of human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies primarily in Australia. The company’s technologies include HyACT drug delivery technology that enhances the delivery of chemotherapeutic agents to cancer cells; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. It also provides generic fondaparinux, an injectable anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, the company develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer. It has collaboration with Monash Institute of Pharmaceutical Science to discover drug candidates for G-Protein coupled receptors; and University of Queensland to discover novel opioid analgesics with reduced side effects. The company was founded in 1995 and is headquartered in Brisbane, Australia.

24 Employees
Last Reported Date: 08/30/13
Founded in 1995

alchemia ltd-sponsored adr (AEMAY) Top Compensated Officers

Group Financial Controller
Total Annual Compensation: A$153.1K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$226.8K
Vice President of Business Development
Total Annual Compensation: A$184.6K
Vice President of Intellectual Property & Tec...
Total Annual Compensation: A$216.0K
Vice President of Drug Discovery
Total Annual Compensation: A$212.5K
Compensation as of Fiscal Year 2013.

alchemia ltd-sponsored adr (AEMAY) Key Developments

Alchemia Limited Appoints Jenni Pilcher as Chief Financial Officer, Effective on September 1, 2014

Alchemia Limited announced the appointment of Ms. Jenni Pilcher as its Chief Financial Officer (CFO). Ms. Pilcher brings extensive financial leadership experience to Alchemia. She is currently the CFO of Mesoblast, where she has been part of the executive team for the past seven years, and she also serves as Company Secretary. Jenni's appointment is effective on September 1, 2014.

Alchemia Limited Announces First Patient Enrolled into Clinical Trial of HA-Irinotecan and Erbitux

Alchemia Limited announced that the first patient has been enrolled into the new clinical trial of HA-Irinotecan and Erbitux (cetuximab); the CHIME trial. This clinical trial is being conducted as an Investigator-Sponsored trial and is jointly supported by Alchemia and Merck Serono SA (Merck Serono). The trial is being led by principal investigator, Associate Professor Peter Gibbs. The primary objective of this study is to evaluate the safety of Alchemia's lead HyACT drug, HA-Irinotecan, as part of the FOLFIRI treatment regimen, in combination with Erbitux. The CHIME trial will enrol approximately 50 patients who are candidates for second-line treatment of metastatic colorectal cancer (mCRC) and it will take place at six to ten sites around Australia. The trial is scheduled to run for approximately 24 months.

Alchemia Limited Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 10:20 AM

Alchemia Limited Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 10:20 AM. Venue: Sheraton Hong Kong Hotel & Towers, 20 Nathan Road, Kowloon, Hong Kong. Speakers: Thomas Liquard, Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMAY:US $0.00 USD 0.00

AEMAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMAY.
View Industry Companies
 

Industry Analysis

AEMAY

Industry Average

Valuation AEMAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD-SPONSORED ADR, please visit www.alchemia.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.